meningococcal infections

Summary

Summary: Infections with bacteria of the species NEISSERIA MENINGITIDIS.

Top Publications

  1. ncbi Global epidemiology of meningococcal disease
    Lee H Harrison
    Infectious Diseases Epidemiology Research Unit, University of Pittsburgh School of Medicine and Graduate School of Public Health, 521 Parran Hall, 130 DeSoto Street, Pittsburgh, PA 15261, United States
    Vaccine 27:B51-63. 2009
  2. pmc Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms
    M C Maiden
    Wellcome Trust Centre for the Epidemiology of Infectious Disease, Department of Zoology, University of Oxford, Oxford OX1 3PS, United Kingdom
    Proc Natl Acad Sci U S A 95:3140-5. 1998
  3. ncbi Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity
    Martin C J Maiden
    Dept of Zoology, John Radcliffe Hospital, Oxford University, Oxford, United Kingdom
    J Infect Dis 197:737-43. 2008
  4. ncbi Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
    Caroline L Trotter
    Statistics, Economics, and Modelling Department, Health Protection Agency Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Lancet 364:365-7. 2004
  5. ncbi Genetic analysis of meningococci carried by children and young adults
    Heike Claus
    Institute for Hygiene and Microbiology, University of Wurzburg, Wurzburg, Germany
    J Infect Dis 191:1263-71. 2005
  6. pmc Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
    Caroline L Trotter
    Department of Social Medicine, University of Bristol, Canynge Hall, Bristol, UK
    Expert Rev Vaccines 8:851-61. 2009
  7. ncbi Meningococcal carriage by age: a systematic review and meta-analysis
    Hannah Christensen
    School of Social and Community Medicine, University of Bristol, Bristol, UK
    Lancet Infect Dis 10:853-61. 2010
  8. ncbi A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
    M Knuf
    Zentrum für Kinder und Jugendmedizin, Johannes Gutenberg University, Germany
    Vaccine 28:744-53. 2010
  9. ncbi Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial
    Nicoletta Gossger
    Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre and Department of Paediatrics, University of Oxford, Oxford, United Kingdom
    JAMA 307:573-82. 2012
  10. pmc Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival
    Hebert Echenique-Rivera
    Novartis Vaccines and Diagnostics, Siena, Italy
    PLoS Pathog 7:e1002027. 2011

Detail Information

Publications256 found, 100 shown here

  1. ncbi Global epidemiology of meningococcal disease
    Lee H Harrison
    Infectious Diseases Epidemiology Research Unit, University of Pittsburgh School of Medicine and Graduate School of Public Health, 521 Parran Hall, 130 DeSoto Street, Pittsburgh, PA 15261, United States
    Vaccine 27:B51-63. 2009
    ....
  2. pmc Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms
    M C Maiden
    Wellcome Trust Centre for the Epidemiology of Infectious Disease, Department of Zoology, University of Oxford, Oxford OX1 3PS, United Kingdom
    Proc Natl Acad Sci U S A 95:3140-5. 1998
    ....
  3. ncbi Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity
    Martin C J Maiden
    Dept of Zoology, John Radcliffe Hospital, Oxford University, Oxford, United Kingdom
    J Infect Dis 197:737-43. 2008
    ..The impact of this intervention on asymptomatic carriage of meningococci was investigated to establish whether serogroup replacement or protection by herd immunity occurred...
  4. ncbi Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
    Caroline L Trotter
    Statistics, Economics, and Modelling Department, Health Protection Agency Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Lancet 364:365-7. 2004
    ..The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained...
  5. ncbi Genetic analysis of meningococci carried by children and young adults
    Heike Claus
    Institute for Hygiene and Microbiology, University of Wurzburg, Wurzburg, Germany
    J Infect Dis 191:1263-71. 2005
    ..The relationship between meningococcal genotype and capsular polysaccharide, the principal virulence factor and vaccine component, was investigated in carried meningococci isolated from 8000 children and young adults in Bavaria, Germany...
  6. pmc Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
    Caroline L Trotter
    Department of Social Medicine, University of Bristol, Canynge Hall, Bristol, UK
    Expert Rev Vaccines 8:851-61. 2009
    ..The magnitude of the herd effects following MCC vaccination was largely unanticipated, and has important consequences for the design and evaluation of new meningococcal vaccines...
  7. ncbi Meningococcal carriage by age: a systematic review and meta-analysis
    Hannah Christensen
    School of Social and Community Medicine, University of Bristol, Bristol, UK
    Lancet Infect Dis 10:853-61. 2010
    ..Previous studies have shown that carriage rates vary by age and setting; however, few have assessed carriage across all ages. We aimed to estimate the age-specific prevalence of meningococcal carriage...
  8. ncbi A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
    M Knuf
    Zentrum für Kinder und Jugendmedizin, Johannes Gutenberg University, Germany
    Vaccine 28:744-53. 2010
    ..The safety profile was comparable to licensed controls. The new ACWY-TT conjugate vaccine promises high seroprotection levels against meningococcal disease from 1 year of age...
  9. ncbi Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial
    Nicoletta Gossger
    Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre and Department of Paediatrics, University of Oxford, Oxford, United Kingdom
    JAMA 307:573-82. 2012
    ..In the absence of an effective vaccine, serogroup B Neisseria meningitidis (MenB) remains a major cause of invasive disease in early childhood in developed countries...
  10. pmc Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival
    Hebert Echenique-Rivera
    Novartis Vaccines and Diagnostics, Siena, Italy
    PLoS Pathog 7:e1002027. 2011
    ..This increased knowledge of how Nm responds to adaptation in blood could also be helpful to develop diagnostic and therapeutic strategies to control the devastating disease cause by this microorganism...
  11. ncbi Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study
    María Elena Santolaya
    Departamento de Pediatria, Hospital Dr Luis Calvo Mackenna, Facultad de Medicina, Universidad de Chile, Santiago, Chile
    Lancet 379:617-24. 2012
    ..We assessed immunogenicity and tolerability of a four-component vaccine (4CMenB) in adolescents...
  12. pmc Meningococcal carriage and disease--population biology and evolution
    Dominique A Caugant
    WHO Collaborating Centre for Reference and Research on Meningococci, Norwegian Institute of Public Health, Oslo, Norway
    Vaccine 27:B64-70. 2009
    ....
  13. ncbi Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years
    Lars Ostergaard
    Department of Infectious Diseases, Aarhus University Hospital, Denmark
    Vaccine 27:161-8. 2009
    ..Our results present five investigational MenACWY-TT conjugate vaccine formulations which are well tolerated and highly immunogenic in adolescents...
  14. pmc Vaccine potential of the Neisseria meningitidis 2086 lipoprotein
    Leah D Fletcher
    Wyeth Vaccines Research, Pearl River, New York 10965, USA
    Infect Immun 72:2088-100. 2004
    ..The rLP2086 family of antigens are candidates worthy of further vaccine development...
  15. ncbi Global epidemiology of meningococcal disease and vaccine efficacy
    Andrew J Pollard
    University of Oxford, John Radcliffe Hospital, Oxford, England
    Pediatr Infect Dis J 23:S274-9. 2004
    ..Comprehensive disease control can be achieved only with the use of vaccines that target all of these disease-causing serogroups...
  16. ncbi Meningococcal surrogates of protection--serum bactericidal antibody activity
    Ray Borrow
    Meningococcal Reference Unit, Health Protection Agency North West Laboratory, Manchester Royal Infirmary, Manchester M13 9WZ, UK
    Vaccine 23:2222-7. 2005
    ..SBA activity as a correlate of protection for evaluating the immune response to meningococcal vaccines is described in this review...
  17. pmc Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity
    Helen Campbell
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Clin Vaccine Immunol 17:840-7. 2010
    ..Modeling suggested that protection against carriage persists for at least 3 years and predicted the stabilization of serogroup C disease at low levels (fewer than 50 cases per year) up to 2015-2016...
  18. pmc Prospects for vaccine prevention of meningococcal infection
    Lee H Harrison
    Infectious Diseases Epidemiology Research Unit, 521 Parran Hall, 130 DeSoto St, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Clin Microbiol Rev 19:142-64. 2006
    ..This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine...
  19. ncbi Serogroup B meningococcal vaccines-an unfinished story
    Manish Sadarangani
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
    Lancet Infect Dis 10:112-24. 2010
    ..Vaccines based on subcapsular antigens have recently produced promising results in early clinical trials, and the disease burden might be substantially reduced over the next few years...
  20. ncbi Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
    Han Qing Jiang
    Pfizer Vaccine Research, 401N Middletown Rd, Pearl River, NY 10965, USA
    Vaccine 28:6086-93. 2010
    ..Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed...
  21. pmc Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana
    Julia Leimkugel
    Swiss Tropical Institute, Basel, Switzerland
    PLoS Med 4:e101. 2007
    ....
  22. ncbi Multilocus sequence typing for global surveillance of meningococcal disease
    Carina Brehony
    The Peter Medawar Building for Pathogen Research and Department of Zoology, University of Oxford, Oxford, UK
    FEMS Microbiol Rev 31:15-26. 2007
    ..The project demonstrates how molecular typing can be combined with epidemiological data via the Internet for global disease surveillance...
  23. ncbi Many carried meningococci lack the genes required for capsule synthesis and transport
    Heike Claus
    Institute for Hygiene and Microbiology, University of Wurzburg, Josef Schneider Strasse 2, 97080 Wurzburg, Germany
    Microbiology 148:1813-9. 2002
    ....
  24. ncbi Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis
    Johan Holst
    Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, P O Box 4404 Nydalen, Oslo NO 0403, Norway
    Vaccine 27:B3-12. 2009
    ..The desire to have a global vaccine strategy that enables susceptible individuals to be protected against all the relevant serogroups of meningococcal disease may become a reality...
  25. ncbi Interactions between Neisseria meningitidis and the complement system
    Muriel C Schneider
    Centre for Molecular Microbiology and Infection, Department of Infectious Diseases, Flowers Building, Armstrong Road, Imperial College London, London, SW7 2AZ, UK
    Trends Microbiol 15:233-40. 2007
    ..meningitidis avoids complement-mediated killing, and how polymorphisms in genes encoding human complement proteins affect susceptibility to this important human pathogen...
  26. pmc Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera
    Dan M Granoff
    Center for Immunobiology and Vaccine Development, Children s Hospital Oakland Research Institute, Oakland, California 94609, USA
    Infect Immun 77:764-9. 2009
    ..meningitidis in vitro and in vivo. The species specificity of binding of human fH adds another mechanism toward our understanding of why N. meningitidis is strictly a human pathogen...
  27. pmc Transgenic mice expressing human transferrin as a model for meningococcal infection
    Maria Leticia Zarantonelli
    Neisseria Unit, National Reference Centre for the Meningococci, Institut Pasteur, 25 28 Rue du Dr Roux, 75724 Paris Cedex 15, France
    Infect Immun 75:5609-14. 2007
    ..Thus, transgenic mice expressing human transferrin may represent an important advance as a new mouse model for in vivo studies of meningococcal virulence and immunogenicity factors...
  28. ncbi A surveillance network for meningococcal disease in Europe
    Caroline L Trotter
    Immunization Department, Health Protection Agency Centre for Infections, London, UK
    FEMS Microbiol Rev 31:27-36. 2007
    ..The importance of close collaboration between networks of epidemiologists, microbiologists, and the wider scientific and public health community is demonstrated...
  29. ncbi Clinical recognition of meningococcal disease in children and adolescents
    Matthew J Thompson
    Department of Primary Health Care, Old Road Campus, University of Oxford, Oxford, UK
    Lancet 367:397-403. 2006
    ..Meningococcal disease is a rapidly progressive childhood infection of global importance. To our knowledge, no systematic quantitative research exists into the occurrence of symptoms before admission to hospital...
  30. pmc Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
    Nick Andrews
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ, United Kingdom
    Clin Diagn Lab Immunol 10:780-6. 2003
    ....
  31. pmc Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine
    Paul A Kristiansen
    Norwegian Institute of Public Health, Nydalen, 0403 Oslo, Norway
    Clin Vaccine Immunol 18:435-43. 2011
    ..5-1,2-2/F5-8, belonging to the ST-23 complex (47%). All serogroup A isolates were ST-2859 of the ST-5 complex with P1.20,9/F3-1. This study forms a solid basis for evaluating the impact of MenAfriVac introduction on serogroup A carriage...
  32. ncbi MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain
    Philipp Oster
    Chiron Vaccines, Siena, Italy
    Vaccine 23:2191-6. 2005
    ..In conclusion, these findings suggest that MeNZB is safe and is likely to confer protection against systemic group B meningococcal disease caused by the epidemic strain...
  33. pmc Naturally occurring lipid A mutants in neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathy
    Floris Fransen
    Laboratory of Vaccine Research, Netherlands Vaccine Institute, Bilthoven, The Netherlands
    PLoS Pathog 5:e1000396. 2009
    ..Our results provide the first example of a specific mutation in N. meningitidis that can be correlated with the clinical course of meningococcal disease...
  34. pmc Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort
    Fadil A Bidmos
    Department of Genetics, University of Leicester, University Road, Leicester LE1 7RH, United Kingdom
    J Clin Microbiol 49:506-12. 2011
    ..Rapid clonal expansion of potentially pathogenic strains in residential halls has implications for the implementation of public health interventions in university populations...
  35. pmc Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009
    Shamez N Ladhani
    Department, Health Protection Agency Colindale, 61 Colindale Ave, London NW9 5EQ, UK
    Emerg Infect Dis 18:63-70. 2012
    ..The increase in MenY disease requires careful epidemiologic and molecular monitoring...
  36. ncbi Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign
    C L Trotter
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ
    Commun Dis Public Health 5:220-5. 2002
    ....
  37. ncbi The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease
    Lee H Harrison
    Infectious Diseases Epidemiology Research Unit, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Vaccine 29:3363-71. 2011
    ..Innovative approaches are needed to introduce and sustain meningococcal vaccination programs in resource-poor settings with a high incidence of meningococcal disease...
  38. ncbi Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience
    Mamoudou H Djingarey
    WHO Intercountry Support Team, Ouagadougou, Burkina Faso
    Vaccine 30:B40-5. 2012
    ..The Burkina Faso success augurs well for further rollout of the Men A conjugate vaccine in meningitis belt countries...
  39. pmc Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein
    Jay Lucidarme
    Vaccine Evaluation Unit, Health Protection Agency, North West Regional Laboratory, P O Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 18:1002-14. 2011
    ..No fH binding was detected to other ligands among the fHbp-negative strains. The implications of these findings for meningococcal pathogenesis and prevention are discussed...
  40. ncbi Is it exposure to cigarette smoke or to smokers which increases the risk of meningococcal disease in teenagers?
    Pietro G Coen
    Academic Department of Child Health, Queen Mary, University of London, Royal London Hospital, UK
    Int J Epidemiol 35:330-6. 2006
    ..Passive smoking appears to increase the risk of meningococcal disease (MD) in adolescents. Whether this effect is attributable to exposure to cigarette smoke or contact with smokers is unknown...
  41. ncbi Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants
    Kristina A Bryant
    University of Louisville, Louisville, Kentucky, USA
    Pediatrics 127:e1375-85. 2011
    ..A phase III study evaluated the immunogenicity and safety of an investigational Haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY)...
  42. ncbi Prognostic factors in meningococcal disease. Development of a bedside predictive model and scoring system. Barcelona Meningococcal Disease Surveillance Group
    N Barquet
    CAP Gràcia, Institut Catala de la Salut, Barcelona, Spain
    JAMA 278:491-6. 1997
    ..Meningococcal disease is associated with significant morbidity and mortality. Development of a prognostic model based on clinical findings may be useful for identification and management of patients with meningococcal infection...
  43. ncbi Molecular characterization of invasive serogroup Y Neisseria meningitidis strains isolated in the Latin America region
    Raquel Abad
    Reference Laboratory for Meningococci, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo, Km2, 28220 Majadahonda, Madrid, Spain
    J Infect 59:104-14. 2009
    ....
  44. ncbi Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis
    Matthijs C Brouwer
    Department of Neurology, Centre for Infection and Immunity Amsterdam CINIMA, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands
    Lancet Infect Dis 9:31-44. 2009
    ..We also propose an initiative to pool genetic data on pneumococcal and meningococcal meningitis in one biobank...
  45. ncbi Characterization of Neisseria meningitidis strains isolated from invasive meningococcal disease cases in Canada in 2001
    R S W Tsang
    National Microbiology Laboratory, Health Canada, Winnipeg, MB
    Can J Microbiol 49:633-8. 2003
    ..The current data highlight the importance of strain characterization by serogroup, serotype, and serosubtype antigens in providing useful information for the surveillance of meningococcal disease in Canada...
  46. ncbi Meningococcal biofilm growth on an abiotic surface - a model for epithelial colonization?
    Clíona A O'Dwyer
    Molecular Infectious Diseases Group, Department of Paediatrics, Faculty of Medicine, Imperial College London, Wright Fleming Institute, St Mary s Hospital Campus, Norfolk Place, London W2 1PG, UK
    Microbiology 155:1940-52. 2009
    ..Modelling prolonged meningococcal colonization with a sorbarod system offers insight into gene expression during this important, but experimentally relatively inaccessible, phase of human infection...
  47. ncbi Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
    E Miller
    Immunisation Division, Public Health Laboratory Service, Communicable Disease Surveillance Centre, 61 Colindale Avenue, NW9 5EQ, London, UK
    Vaccine 20:S58-67. 2001
    ..Surveillance of the prevalent serogroups and serosubtypes among invasive case isolates has shown no evidence of any capsular switching to serogroup B during the first 18 months of the MCC vaccination programme...
  48. pmc Simultaneous approach for nonculture PCR-based identification and serogroup prediction of Neisseria meningitidis
    M K Taha
    Unité des Neisseria and Centre National de Référence des Méningocoques, Institut Pasteur, 75724 Paris Cedex 15, France
    J Clin Microbiol 38:855-7. 2000
    ..meningitidis of culture-proven meningococcal diseases and confirmed this diagnosis in 35% of suspected samples. This approach could be useful when culture fails to isolate N. meningitidis...
  49. pmc The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB
    D R Martin
    Insitute of Environmental Science and Research ESR, Porirua, New Zealand
    Clin Vaccine Immunol 13:486-91. 2006
    ..4 epitope of the PorA protein supports the public health decision to use a strain-specific vaccine for the control of New Zealand's epidemic of meningococcal disease...
  50. pmc Neisseria meningitidis lactate permease is required for nasopharyngeal colonization
    Rachel M Exley
    The Centre for Molecular Microbiology and Infection, Flowers Building, Imperial College London, Armstrong Rd, London SW7 2AZ, United Kingdom
    Infect Immun 73:5762-6. 2005
    ..Studies with other strains defective for the uptake of specific nutrients should provide valuable information about the environment in which N. meningitidis persists during carriage...
  51. pmc The modular architecture of meningococcal factor H-binding protein
    Peter T Beernink
    Center for Immunobiology and Vaccine Development, Children s Hospital Oakland Research Institute, Oakland, CA 94609, USA
    Microbiology 155:2873-83. 2009
    ..Collectively, the data suggest that recombination between Neisseria meningitidis and N. gonorrhoeae progenitors generated a family of modular, antigenically diverse meningococcal fHbps...
  52. ncbi Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain
    Amparo Larrauri
    Red Nacional de Vigilancia Epidemiológica, Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Sinesio Delgado 6, 28029 Madrid, Spain
    Vaccine 23:4097-100. 2005
    ..Accordingly, there is a need for ongoing re-evaluation of VE and ascertainment of long-term vaccine protection. The findings reported would allow to decide on the advisability of revising current vaccination guidelines...
  53. pmc Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection
    R Borrow
    PHLS Meningococcal Reference Unit, Withington Hospital, Manchester M20 2LR, London NW9 5EQ, United Kingdom
    Infect Immun 69:1568-73. 2001
    ..These results indicated that the majority of toddlers with an rSBA titer between 8 and 64, and some of those with an hSBA result of <4, have mounted a protective immune response with the induction of immunological memory...
  54. pmc Risk and protective factors for meningococcal disease in adolescents: matched cohort study
    Joanna Tully
    Academic Centre for Child Health, Queen Mary s School of Medicine and Dentistry at Barts and The London, University of London, London E1 1BB
    BMJ 332:445-50. 2006
    ..To examine biological and social risk factors for meningococcal disease in adolescents...
  55. pmc Opa+ and Opa- isolates of Neisseria meningitidis and Neisseria gonorrhoeae induce sustained proliferative responses in human CD4+ T cells
    Abdel Rahman Youssef
    Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, Bristol, United Kingdom
    Infect Immun 77:5170-80. 2009
    ..The data also imply that Opa-proficient vaccine preparations may not necessarily inhibit T-cell functions via CEACAM1 binding...
  56. pmc Variation of the factor H-binding protein of Neisseria meningitidis
    Carina Brehony
    Department of Zoology, University of Oxford, OX1 3PS, UK
    Microbiology 155:4155-69. 2009
    ..The highest levels of selection were observed in regions corresponding to epitopes recognized by previously described bactericidal monoclonal antibodies...
  57. ncbi Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom
    Cressida Auckland
    Immunisation Department, Centre for Infections, Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom
    J Infect Dis 194:1745-52. 2006
    ..The meningococcal serogroup C conjugate (MCC) vaccine was introduced into the United Kingdom with licensure based on immunogenicity data not efficacy data...
  58. ncbi Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine
    Jo Anne Welsch
    Children s Hospital Oakland Research Institute, Oakland, CA 94609, USA
    J Immunol 172:5606-15. 2004
    ..meningitidis strains expressing GNA1870 subvariant 1 proteins. The data support GNA1870 as a promising vaccine candidate for prevention of meningococcal group B disease caused by GNA1870 variant 1 strains...
  59. pmc Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000
    Jean Francois Aguilera
    Communicable Disease Surveillance Centre, London, United Kingdom
    Emerg Infect Dis 8:761-7. 2002
    ..No difference in transmission rates following intervention was detected between France and the UK...
  60. ncbi Invasive meningococcal disease in adolescents and young adults
    L H Harrison
    Infectious Diseases Epidemiology Research Unit, University of Pittsburgh, 521 Parran Hall, 130 DeSoto St, Pittsburgh, PA 15261, USA
    JAMA 286:694-9. 2001
    ..Incidence of invasive meningococcal disease has increased recently in persons aged 15 through 24 years...
  61. pmc Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales
    Jay Lucidarme
    Vaccine Evaluation Unit, Health Protection Agency, P O Box 209, Floor 2, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WZ, United Kingdom
    J Clin Microbiol 47:3577-85. 2009
    ..Expression studies and serum bactericidal antibody assays will serve to enhance predictions of coverage and will augment ongoing studies regarding the significance of IS1301 within the ST269 cluster...
  62. pmc Social behavior and meningococcal carriage in British teenagers
    Jenny MacLennan
    University of Oxford, Oxford, United Kingdom
    Emerg Infect Dis 12:950-7. 2006
    ..Social behavior, rather than age or sex, can explain the higher frequency of meningococcal carriage among teenagers. A ban on smoking in public places may reduce risk for transmission...
  63. pmc Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005
    Lee H Harrison
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Infect Dis 201:1208-24. 2010
    ..Neisseria meningitidis changes its capsular phenotype through capsular switching, which has implications for vaccines that do not protect against all serogroups...
  64. pmc Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine
    Jay Lucidarme
    Vaccine Evaluation Unit, Health Protection Agency, P O Box 209, Floor 2, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester M139WZ, United Kingdom
    Clin Vaccine Immunol 17:919-29. 2010
    ..On the basis of genotypic data and predicted immunological cross-reactivity, the potential level of rMenB-OMV vaccine coverage in England and Wales ranges from 66% to 100%...
  65. ncbi Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease
    Sonia Davila
    Infectious Diseases, Genome Institute of Singapore, Singapore
    Nat Genet 42:772-6. 2010
    ..Our study suggests that host genetic variation in these regulators of complement activation plays a role in determining the occurrence of invasive disease versus asymptomatic colonization by this pathogen...
  66. ncbi Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002
    Richard Brooks
    Duke University School of Medicine, Durham, North Carolina, USA
    Clin Infect Dis 43:49-54. 2006
    ..Outbreaks of meningococcal disease are infrequent but important public health events. We characterize outbreak-associated cases in the United States and compare them with sporadic disease...
  67. pmc Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery
    R Booy
    Department of Paediatrics, Imperial College School of Medicine, St Mary's Hospital, Norfolk Place, London W2 1PG, UK
    Arch Dis Child 85:386-90. 2001
    ....
  68. ncbi Impact of meningococcal C conjugate vaccine in the UK
    P Balmer
    Meningococcal Reference Unit, Manchester PHL, Withington Hospital
    J Med Microbiol 51:717-22. 2002
    ..Surveillance of the genotypic and phenotypic characteristics of invasive and carriage isolates has shown no evidence to date of capsular switching from serogroup C to serogroup B...
  69. ncbi High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in Southern Brazil
    Luciana Weidlich
    Programa de Pós graduação em CB Bioquímica, Universidade Federal do Rio Grande do Sul PPGBioq UFRGS, Porto Alegre, RS, Brasil
    J Infect 57:324-31. 2008
    ....
  70. pmc Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis
    Mary E Ramsay
    Public Health Laboratory Service Communicable Disease Surveillance Centre, London, NW9 5EQ
    BMJ 326:365-6. 2003
  71. pmc Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis
    Christoph Schoen
    Institute for Hygiene and Microbiology, University of Wurzburg, Josef Schneider Strasse 2, 97080 Wurzburg, Germany
    Proc Natl Acad Sci U S A 105:3473-8. 2008
    ..meningitidis has emerged as an unencapsulated human commensal from a common ancestor with Neisseria gonorrhoeae and Neisseria lactamica and consecutively acquired the genes responsible for capsule synthesis via horizontal gene transfer...
  72. ncbi PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: implications for the design of an outer membrane protein-based vaccine
    Cecilia Sorhouet Pereira
    Catedra de Microbiologia, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Junin 956, Buenos Aires, Argentina
    J Med Microbiol 57:338-42. 2008
    ..A possible mechanism responsible for altered PorA expression was analysed in two PorA types...
  73. pmc Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans
    Davide Serruto
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 107:3770-5. 2010
    ..We conclude that GNA2132 is an important protective antigen of N. meningitidis and we propose to rename it, Neisserial Heparin Binding Antigen (NHBA)...
  74. ncbi Recognition of the epidemiological significance of Neisseria meningitidis capsular serogroup W135 in the Rio de Janeiro region, Brazil
    David E Barroso
    Grupo de Doenças Virais, Rickettsioses e Febres Hemorrágicas, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, 21040 900, Brasil
    Mem Inst Oswaldo Cruz 102:773-5. 2007
    ..We report here the emergence of serogroup W135 meningococcal disease causing endemic and case cluster in Rio de Janeiro during the first years of this new century...
  75. pmc Transcriptome analysis of Neisseria meningitidis during infection
    Guido Dietrich
    Institute for Hygiene and Microbiology, University of Wurzburg, Josef Schneider Strasse 2, 97080 Wurzburg, Germany
    J Bacteriol 185:155-64. 2003
    ..meningitidis and could demonstrate the importance of gene regulation on the transcriptional level during different stages of meningococcal infection...
  76. pmc Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine
    Dominique A Caugant
    WHO Collaborating Centre for Reference and Research on Meningococci, Norwegian Institute of Public Health, Oslo, Norway
    PLoS ONE 7:e46019. 2012
    ....
  77. ncbi Detection of a geographical and endemic cluster of hyper-invasive meningococcal strains
    Sophie Bertrand
    National Reference Centre for Neisseria meningitidis, Bacterial Diseases Division, Communicable and Infectious Diseases, Scientific Institute of Public Health, J Wytsman Street, 14 16, B 1050 Brussels, Belgium
    Microbes Infect 13:684-90. 2011
    ..This study showed that the combination of molecular tools with classical methods enabled reliable outbreak detection as well as a cluster identification...
  78. ncbi Reconsideration of the use of meningococcal polysaccharide vaccine
    Dan M Granoff
    Center for Immunobiology and Vaccine Development, Children s Hospital Oakland Research Institute, Oakland, CA, USA
    Pediatr Infect Dis J 26:716-22. 2007
    ....
  79. pmc Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis
    Vincent E Weynants
    GlaxoSmithKline Biologicals, Rue de l Institut 89, B 1330 Rixensart, Belgium
    Infect Immun 75:5434-42. 2007
    ..With minor OMPs, this threshold is reached when more than one antigen is targeted, and this allows cross-protection...
  80. ncbi Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States
    Xin Wang
    Meningitis and Vaccine Preventable Disease Branch, Division of Bacterial Diseases, National Center of Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, United States
    Vaccine 29:4739-44. 2011
    ....
  81. ncbi The changing and dynamic epidemiology of meningococcal disease
    Scott A Halperin
    Canadian Center for Vaccinology, Dalhousie University, The IWK Health Centre, and Capital Health, Halifax, Canada
    Vaccine 30:B26-36. 2012
    ..Continued surveillance of meningococcal disease is essential; ongoing global efforts to improve the completeness of reporting are required...
  82. ncbi Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis
    Bas van de Waterbeemd
    Department of Vaccinology, National Institute for Public Health and Environment RIVM, Bilthoven, The Netherlands
    Vaccine 30:3683-90. 2012
    ..High functional immunogenicity and low toxicity of the optimized vaccine were also confirmed. The EDTA extraction is therefore a robust process step which produces high quality OMV if harvest and pH are controlled accurately...
  83. pmc Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis
    David S Stephens
    Emory University, Robert W Woodruff Health Sciences Center, 1440 Clifton Road, NE, Atlanta, GA 30322, USA
    Vaccine 27:B71-7. 2009
    ..We review the general status of our knowledge of pathogenesis of meningococcal carriage, transmission and virulence behavior with particular emphasis on the relevance of research on this topic to vaccine development...
  84. ncbi Pathogenesis and diagnosis of human meningococcal disease using immunohistochemical and PCR assays
    Jeannette Guarner
    Infectious Disease Pathology Activity, Division of Viral Rickettsial Diseases, National Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Am J Clin Pathol 122:754-64. 2004
    ..Immunohistochemical analysis determined the distribution of meningococci and meningococcal antigens in tissue samples, allowing better insights into N meningitidis pathogenesis...
  85. ncbi Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention
    Marco Aurelio Palazzi Sáfadi
    Department of Pediatrics, Santa Casa de Sao Paulo School of Medicine, Sao Paulo, Brazil
    Neurol Res 32:263-71. 2010
    ..In addition to discussing recent changes in the epidemiology of meningococcal disease in the region, we also analyse the development and potential impact of new vaccines on the prevention of meningococcal disease...
  86. ncbi Sequence conservation of pilus subunits in Neisseria meningitidis
    Ana Cehovin
    The Centre for Molecular Microbiology and Infection, CMMI Flowers Building, Imperial College London, Armstrong Road, London SW7 2AZ, UK
    Vaccine 28:4817-26. 2010
    ..These data have important implications for the re-consideration of pilus subunits as vaccine antigens...
  87. ncbi Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process
    Bas van de Waterbeemd
    Netherlands Vaccine Institute, Unit Research and Development, The Netherlands
    Vaccine 28:4810-6. 2010
    ..With comparable toxicity and yield, no aggregation and cross-protection against other PorA subtypes, these OMV vaccines are potentially safe and effective for parenteral use in humans...
  88. ncbi The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002
    Béhima Koumaré
    WHO Communicable Diseases Surveillance and Response, Abidjan, Ivory Coast
    Vaccine 25:A37-41. 2007
    ..We report here the results of the laboratory-based surveillance and the characteristics of the epidemic clone...
  89. ncbi Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada
    Philippe De Wals
    Department of Social and Preventive Medicine, Laval University, Quebec City, Canada
    Pediatr Infect Dis J 30:566-9. 2011
    ..In 2002, 1 C-MCV dose was routinely offered to children 12 months of age...
  90. ncbi Neisseria meningitidis phenotypic markers and septicaemia, disease progress and case-fatality rate of meningococcal disease: a 20-year population-based historical follow-up study in a Danish county
    Elise Snitker Jensen
    Department of Clinical Epidemiology, Aalborg and Aarhus University Hospital, Stengade 10, 2nd Floor, DK 9000 Aalborg, Denmark
    J Med Microbiol 52:173-9. 2003
    ..In conclusion, phenotypes B : 15 : P1.7,16 and C : 2a : P1.2,5 were predictors of an increased CFR. The high prevalence of phenotype B : 15 : P1.7,16 contributed to increased overall IR and CFR during 1990-99...
  91. ncbi Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups
    M N Tsolia
    Second Dept of Pediatrics P and A Kyriakou Children s Hospital, University of Athens School of Medicine, Thivon and Levadias St, 115 27, Athens, Greece
    Eur J Clin Microbiol Infect Dis 25:449-56. 2006
    ..Serogroup B is predominant in our area, and the introduction of an effective vaccine against it is a priority. Serogroup A has emerged as the second most common serogroup, but the illness associated with it is milder...
  92. pmc NalP-mediated proteolytic release of lactoferrin-binding protein B from the meningococcal cell surface
    Virginie Roussel-Jazédé
    Department of Molecular Microbiology, Institute of Biomembranes, Utrecht University, Utrecht, Netherlands
    Infect Immun 78:3083-9. 2010
    ..Since antibodies directed against LbpB are found in convalescent-patient sera, the release of an immunogenic protein as LbpB may represent a novel means for N. meningitidis to escape the human immune response...
  93. pmc Differential modulation of TNF-alpha-induced apoptosis by Neisseria meningitidis
    Ala Eddine Deghmane
    Institut Pasteur, Invasive Bacterial Infections Unit, Paris, France
    PLoS Pathog 5:e1000405. 2009
    ..meningitidis. However, our data strongly suggest that carriage isolates of meningococci reduce inflammatory response and apoptosis induction, resulting in the protection of their ecological niche at the human nasopharynx...
  94. pmc Neisseria meningitidis intermediately resistant to penicillin and causing invasive disease in South Africa in 2001 to 2005
    Mignon du Plessis
    National Institute for Communicable Diseases of the National Health Laboratory Service, University of the Witwatersrand, Johannesburg, South Africa
    J Clin Microbiol 46:3208-14. 2008
    ..This is the first report describing the prevalence and molecular epidemiology of Pen(i) meningococcal isolates from sub-Saharan Africa...
  95. ncbi Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
    Matthew D Snape
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX3 7LJ, United Kingdom
    Clin Infect Dis 43:1387-94. 2006
    ....
  96. pmc Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study
    Annelies Wilder-Smith
    Travellers Health and Vaccination Centre, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433
    BMJ 325:365-6. 2002
  97. pmc Two-partner secretion systems of Neisseria meningitidis associated with invasive clonal complexes
    Peter van Ulsen
    Department of Molecular Microbiology, Utrecht University, 3584 CH Utrecht, The Netherlands
    Infect Immun 76:4649-58. 2008
    ..Together, our data indicate that TPS systems may contribute to the virulence of N. meningitidis...
  98. ncbi Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus
    Stefania Bambini
    Novartis V and D, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 27:2794-803. 2009
    ..Sequencing each gene in the different strains will be important to evaluate antigen conservation and assortment and to allow a future prediction of potential vaccine coverage...
  99. ncbi Hyperinvasive genotypes of Neisseria meningitidis in France
    M L Zarantonelli
    Neisseria Unit, National Reference Centre for Meningococci, Institut Pasteur, Paris, France
    Clin Microbiol Infect 14:467-72. 2008
    ....
  100. pmc Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains
    Amanda J Beddek
    Centre for Biodiscovery and School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
    Infect Immun 77:2989-94. 2009
    ..Moreover, the capsule switch described here has arisen from the exchange of the entire capsule locus...
  101. ncbi Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens
    Susanne Jacobsson
    National Reference Laboratory for Pathogenic Neisseria, Department of Clinical Microbiology, Orebro University Hospital, Orebro, Sweden
    Vaccine 24:2161-8. 2006
    ..Based on gene prevalence and conservation, all three antigens are promising candidates for an effective meningococcal vaccine against all N. meningitidis irrespective of serogroup...

Research Grants22

  1. Complement Activation on Neisseria meningitidis
    Sanjay Ram; Fiscal Year: 2013
    ..provided by applicant): Complement (C) is a key arm of innate immune defenses against invasive meningococcal infections. Neisseria meningitidis (Nm) have evolved several sophisticated mechanisms to evade host C...
  2. Prophage-associated virulence factors in pathogenic Neisseria species
    ANNA KARLS; Fiscal Year: 2009
    ..Despite the use of chemotherapeutics, 10-40% of invasive meningococcal infections are fatal and 10-15% of survivors have serious sequelae, including mental retardation and deafness.
  3. Role of sialylated LPS in H. influenzae otitis media
    Richard Goldstein; Fiscal Year: 2003
    ..virulence factor in AOM, analogous to the virulence role of sialic acid of LPS in gonococcal and meningococcal infections. These studies capitalized upon the availability of: (i) isogenic pairs of wild-type and LPS sialylation ..
  4. Forensic Detection of Salmonella Resistance and Subtype
    Lee Harrison; Fiscal Year: 2005
    ..enterica and 2) molecular methods for rapid outbreak detection among S. enterica serovars. ..
  5. Neisseria meningitidis antigens expressed in infection
    Dan Granoff; Fiscal Year: 2005
    ..meningitidis disease, including group B strains for which there is currently no vaccine available. Also, characterization of gene expression in an in vivo model will lead to a better understanding of meningococcal pathogenesis. ..
  6. Molecular basis meningococcal group A capsular immunity
    Dan Granoff; Fiscal Year: 2007
    ..abstract_text> ..
  7. CLINICAL RESEARCH CURRICULUM AWARD
    David Stephens; Fiscal Year: 2004
    ..abstract_text> ..
  8. Molecular bssis of mef-mediated antibiotic resistance in Streptococcus pneumoniae
    David S Stephens; Fiscal Year: 2010
    ..pneumoniae. ..
  9. Center for Clinical and Translational Science Advancement at Emory
    David Stephens; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  10. MENINGOCOCCAL LIPOOLIGOSACCHARIDE & MUCOSAL PATHOGENESIS
    David Stephens; Fiscal Year: 2007
    ..b>Meningococcal infections remain devastating in the United States and worldwide...
  11. Regulation of Capsule Biosynthesis in N. meningitidis
    David Stephens; Fiscal Year: 2006
    ....
  12. Evaluation of Anti-endotoxin Vaccine for Human Use
    Alan Cross; Fiscal Year: 2006
    ..If successful, these studies will lead to phase II and Ill studies for the prevention and treatment of sepsis. ..
  13. SIALIC ACID MODULATION REGULATES NEUTROPHIL DIAPEDESIS
    Alan Cross; Fiscal Year: 2002
    ..These studies will define a new mechanism for a rapidly adaptable, temporally- restricted local response to inflammation. This proposal will provide new targets and additional approaches to the treatment of inflammation. ..
  14. INTERFERON Y MEDIATES ANTI E COLI DEFENSES AND SEPSIS
    Alan Cross; Fiscal Year: 2001
    ..The demonstration of a spectrum of responses to LPS in these studies may identify the earliest changes in cytokine responses that predict the development of sepsis. ..
  15. Immunoglobulin Allotypes in Hepatitis C Virus Infection
    JANARDAN PANDEY; Fiscal Year: 2008
    ..Results of this investigation will advance our understanding of the role of host genetic factors in clearance and persistence of hepatitis C virus infection. ..
  16. Alteration of host iron homeostasis by Neisseria
    ROBERT BONNAH; Fiscal Year: 2005
    ..These studies may lead to novel treatment strategies, since withholding iron can arrest bacterial growth. ..
  17. Early events during infection with anthrax
    Alan Cross; Fiscal Year: 2006
    ..abstract_text> ..
  18. Role of Sialidase in Pulmonary Host Defenses and Acute Lung Injury
    Alan Cross; Fiscal Year: 2010
    ..Since inhibitors of sialidase are commercially available, these studies will provide the experimental rationale for testing a new therapeutic approach to the treatment of lung injury. ..
  19. Challenge with B pertussis--Pathogenesis & Immunology
    Sylvia Yeh; Fiscal Year: 2005
    ..We hope to greatly refine the understanding of B. pertussis and develop improved means for diagnosis and prevention of disease in all age groups. ..
  20. Envirnomental Health Specialist Network
    RICHARD NORMAN DANILA; Fiscal Year: 2010
    ..abstract_text> ..
  21. Unique Neisseria Meningitidis B Capsular Epitopes
    GREGORY MOE; Fiscal Year: 2009
    ..Thus, this proposal offers a novel approach to develop a protective PS-based vaccine that avoids safety concerns of eliciting autoantibodies and for understanding structural differences between group B capsular and host PSA antigens. ..
  22. MIMETICS OF CAPSULAR EPITOPES OF NEISSERIA MENINGITIDIS
    GREGORY MOE; Fiscal Year: 2004
    ..The results also may identify new candidate molecules for inclusion in a future vaccine for prevention of NmB disease. ..